|
|
Article: Neutron Signs Letter of Intent to Acquire up to 67% Interest in Development Stage Bio-Pharmaceutical Company; Products Include Treatment for Female Sexual Arousal Disorder (FSAD).
- Article from:
- PR Newswire
- Article date:
- March 10, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WHITE ROCK, BC, March 10 /PRNewswire-FirstCall/ --
Highlights:
-----------
- Signs Letter of Intent to acquire up to a 67% interest in a
development stage bio-pharmaceutical company focused on the treatment
of Female Sexual Arousal Disorder (FSAD).
- Endeavors to become one of the first companies to gain FDA approval
and deliver a product for the treatment of FSAD.
Neutron Enterprises, Inc.(NASDAQBB: NTRN), through its wholly owned subsidiary University Medical Enterprises Inc., announced today it had signed a Letter of Intent to acquire up to a 67% interest in a privately held development stage bio-pharmaceutical drug ...